ECSP055609A - "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor" - Google Patents

"Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"

Info

Publication number
ECSP055609A
ECSP055609A EC2005005609A ECSP055609A ECSP055609A EC SP055609 A ECSP055609 A EC SP055609A EC 2005005609 A EC2005005609 A EC 2005005609A EC SP055609 A ECSP055609 A EC SP055609A EC SP055609 A ECSP055609 A EC SP055609A
Authority
EC
Ecuador
Prior art keywords
pain
kinase inhibitors
ikb
treatment
inhibitors
Prior art date
Application number
EC2005005609A
Other languages
English (en)
Inventor
Martin Michaelis
Olaf Ritzeler
Gerhard Jaehne
Karl Rudolphi
Gerd Geisslinger
Hans-Georg Schaible
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of ECSP055609A publication Critical patent/ECSP055609A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La invención se refiere al uso de inhibidores de la lkB-quinasa que son adecuados para la preparación de medicamentos para tratar dolores. Los inhibidores adecuados son compuestos de las fórmulas (I) y (Ia).
EC2005005609A 2002-08-17 2005-02-17 "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor" ECSP055609A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie

Publications (1)

Publication Number Publication Date
ECSP055609A true ECSP055609A (es) 2005-04-18

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005609A ECSP055609A (es) 2002-08-17 2005-02-17 "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"

Country Status (33)

Country Link
EP (1) EP1531819B1 (es)
JP (1) JP4504811B2 (es)
KR (2) KR20110135428A (es)
CN (1) CN100398107C (es)
AR (1) AR043045A1 (es)
AT (1) ATE418336T1 (es)
AU (1) AU2003271555B2 (es)
BR (1) BR0313555A (es)
CA (1) CA2495455C (es)
CO (1) CO5690585A2 (es)
CR (1) CR7716A (es)
CY (1) CY1108874T1 (es)
DE (2) DE10237723A1 (es)
DK (1) DK1531819T3 (es)
EC (1) ECSP055609A (es)
ES (1) ES2320118T3 (es)
HR (1) HRP20050041B1 (es)
IL (1) IL166780A (es)
MA (1) MA27334A1 (es)
MX (1) MXPA05001218A (es)
MY (1) MY138059A (es)
NO (1) NO334309B1 (es)
OA (1) OA12907A (es)
PL (1) PL212356B1 (es)
PT (1) PT1531819E (es)
RS (1) RS51878B (es)
RU (1) RU2320338C2 (es)
SI (1) SI1531819T1 (es)
TN (1) TNSN05044A1 (es)
TW (1) TWI325782B (es)
UA (1) UA80837C2 (es)
WO (1) WO2004022057A1 (es)
ZA (1) ZA200500323B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5790440B2 (ja) 2010-12-01 2015-10-07 住友化学株式会社 ピリミジン化合物およびその有害生物防除用途
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013083553A1 (en) 2011-12-06 2013-06-13 Sanofi Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
AU2015283052B2 (en) * 2014-07-03 2020-01-02 Sanofi 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid ((s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl)-amide for use in the treatment of pain associated to osteoarthritis
CN112513025B (zh) 2018-07-16 2025-03-25 诺华股份有限公司 用于制备苯基哌啶基吲哚衍生物的化学方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1194425E (pt) * 1999-06-23 2005-10-31 Aventis Pharma Gmbh Benzimidazoles substituidos
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
HRP20050041A2 (hr) 2006-04-30
BR0313555A (pt) 2005-07-12
HRP20050041B1 (hr) 2013-07-31
EP1531819B1 (de) 2008-12-24
PT1531819E (pt) 2009-02-18
SI1531819T1 (sl) 2009-06-30
KR20110135428A (ko) 2011-12-16
MY138059A (en) 2009-04-30
ATE418336T1 (de) 2009-01-15
AU2003271555A1 (en) 2004-03-29
KR101119845B1 (ko) 2012-02-28
MA27334A1 (fr) 2005-05-02
JP2005539053A (ja) 2005-12-22
CA2495455C (en) 2011-01-11
CA2495455A1 (en) 2004-03-18
TW200417370A (en) 2004-09-16
KR20050058339A (ko) 2005-06-16
WO2004022057A1 (de) 2004-03-18
HK1079426A1 (en) 2006-04-07
CN1674899A (zh) 2005-09-28
ZA200500323B (en) 2006-02-22
NO20051339L (no) 2005-05-03
CY1108874T1 (el) 2014-07-02
CR7716A (es) 2008-11-25
PL212356B1 (pl) 2012-09-28
RS51878B (sr) 2012-02-29
NO334309B1 (no) 2014-02-03
CN100398107C (zh) 2008-07-02
EP1531819A1 (de) 2005-05-25
RU2005107419A (ru) 2005-08-10
DE10237723A1 (de) 2004-07-08
AR043045A1 (es) 2005-07-13
MXPA05001218A (es) 2005-05-16
TNSN05044A1 (en) 2007-05-14
JP4504811B2 (ja) 2010-07-14
CO5690585A2 (es) 2006-10-31
AU2003271555B2 (en) 2009-03-26
OA12907A (en) 2006-10-13
PL373568A1 (en) 2005-09-05
ES2320118T3 (es) 2009-05-19
DE50310980D1 (de) 2009-02-05
UA80837C2 (uk) 2007-11-12
RS20050070A (sr) 2007-06-04
DK1531819T3 (da) 2009-04-20
IL166780A (en) 2011-11-30
IL166780A0 (en) 2006-01-15
TWI325782B (en) 2010-06-11
RU2320338C2 (ru) 2008-03-27

Similar Documents

Publication Publication Date Title
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
UY28342A1 (es) Nuevos compuestos
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
ECSP941122A (es) Derivados de 5-arilindoles
SV2003000925A (es) Derivados espirotriciclicos nuevos y su uso como inhibidores de fosfodiesterasa-7
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
AR032136A1 (es) Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
CL2004000647A1 (es) Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
PA8432901A1 (es) Compuestos de piridilpirrol
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
PA8555501A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica